Apimeds Pharmaceuticals Us, Inc. APUS
We take great care to ensure that the data presented and summarized in this overview for Apimeds Pharmaceuticals US, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in APUS
Top Purchases
Top Sells
About APUS
Insider Transactions at APUS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 16
2025
|
Christopher Kim Chairman and CMO |
BUY
Grant, award, or other acquisition
|
Direct |
250,000
+47.39%
|
-
|
|
May 16
2025
|
Erik C. Emerson Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
750,000
+50.0%
|
-
|
|
May 14
2025
|
Christopher Kim Chairman and CMO |
BUY
Open market or private purchase
|
Direct |
7,730
+21.94%
|
$7,730
$1.86 P/Share
|
|
May 13
2025
|
Christopher Kim Chairman and CMO |
BUY
Open market or private purchase
|
Direct |
19,770
+50.0%
|
$19,770
$1.82 P/Share
|
|
May 12
2025
|
Jakap Koo Director |
BUY
Open market or private purchase
|
Direct |
28,500
+4.24%
|
$28,500
$1.99 P/Share
|
|
May 12
2025
|
Inscobee Inc. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
44,041
+2.12%
|
$88,082
$2.6 P/Share
|
|
May 12
2025
|
Inscobee Inc. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
253,092
+2.82%
|
$506,184
$2.6 P/Share
|
|
May 12
2025
|
Inscobee Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
500,000
+20.12%
|
$2,000,000
$4.0 P/Share
|
Last 12 Months Summary
Buy / Acquisition
1.85M
Shares
From
6
Insiders
| Grant, award, or other acquisition | 1M shares |
|---|---|
| Conversion of derivative security | 297K shares |
| Open market or private purchase | 556K shares |
Sell / Disposition
0
Shares
From
0
Insiders